Dofetilide and Rythmol Extended Release
Determining the interaction of Dofetilide and Rythmol Extended Release and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using dofetilide together with propafenone can increase the risk of an irregular heart rhythm that may be serious and potentially life-threatening. You may be more susceptible if you have a heart condition called congenital long QT syndrome, other cardiac diseases, conduction abnormalities, or electrolyte disturbances (for example, magnesium or potassium loss due to severe or prolonged diarrhea or vomiting). Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact. You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, shortness of breath, or heart palpitations during treatment with these medications. In addition, you should let your doctor know if you experience signs of electrolyte disturbance such as weakness, tiredness, drowsiness, confusion, muscle pain, cramps, dizziness, nausea, or vomiting. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:GENERALLY AVOID: Dofetilide should not be used with Class I or other Class III antiarrhythmic agents due to the potential for additive effects on myocardial refractoriness. Many of these agents, including dofetilide, can also cause prolongation of the QT interval, thus concomitant use may increase the risk of ventricular arrhythmias such as ventricular tachycardia and torsade de pointes.
MANAGEMENT: Class I (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, ibutilide, sotalol) antiarrhythmic agents should be withheld for at least 3 half-lives before administering dofetilide. In the case of amiodarone with its unpredictable pharmacokinetics, dofetilide should not be initiated until serum amiodarone levels are below 0.3 mcg/mL or amiodarone has been withdrawn for at least three months.
- "Product Information. Tikosyn (dofetilide)" Pfizer US Pharmaceuticals, Atlanta, GA.
Generic Name: propafenone
Brand name: Rythmol, Rythmol SR
Synonyms: Rythmol SR
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Dofetilide-Rythmol SR
- Dofetilide-Ryvent
- Dofetilide-Ryzodeg 70/30
- Dofetilide-Ryzolt
- Rythmol Extended Release-DOK
- Rythmol Extended Release-Dok Plus
- Rythmol Extended Release-Dolasetron
- Rythmol Extended Release-Dolasetron Injection
- Rythmol Extended Release-Dolasetron Mesylate
- Rythmol Extended Release-Dolasetron Oral, Intravenous